Szczepańska Maria, Tobis Anna, Schneiberg Barbara, Szprynger Krystyna, Kobos Edyta, Morawiec-Knysak Aurelia
Klinika Pediatrii, Nefrologii i Endokrynologii Dzieciecej Slaskiej Akademii Medycznej w Zabrzu.
Pol Merkur Lekarski. 2005 Jan;18(103):22-8.
The study aimed at evaluation of chronic hepatitis treatment results in children previously treated from nephrological indications in 1994-2002 years.
Examination was performed in 42 children in the age 10.2 +/- 4.8 years at the onset time of interferon (INF) treatment application. In 30 children (71.4%) chronic HBV infection, in 8 (19.1%) - HCV infection, in 4 (9.5%) - mixed HBV and HCV infection in phase of replication was revealed. Among examined children in 26 (61.9%) symptoms of glomerulonephritis were previously reported, in 17 (40.5%) - symptoms of nephrotic syndrome; in 9 (21.4%) - chronic renal failure was observed. 22 children received prednisone treatment. Concentrations of albumin, gamma- globulin, bilirubin, haemoglobin, creatinine, haematocrit, leukocytosis, activity of alanine aminotransferase (ALT), chronic hepatitis markers, before, during and 6 and 12 months after treatment termination were evaluated. IFN alpha-2a, alpha-2b and human recombined IFN-alpha were applied
In 22 (52.4%) children ALT values before treatment not exceeded 100 IU/l. Liver biopsy was performed in 39 children. In 18 (46.2%) - high activity of inflammatory process was revealed; only in 5 of them with ALT activity above 100 IU/l. Higher leukocytosis at the beginning of treatment was accompanied by diminished activity of inflammatory process. In 14/34 children seroconversion was obtained in HBe markers, in 4/12 HCV-RNA elimination occurred after the 1st course of IFN. Only in 5 (11.9%) children treatment was stopped because of side effects (not connected with urinary tract), in 1 - because of relapse of main disease. 2nd course was applied in 13 children. In 2 - seroconversion in HBe markers was obtained.
Considering the small number of examined children full evaluation of chronic hepatitis treatment efficacy is not possible. It seems comparable as observed in population of children without the risk of nephropathies. IFN treatment in children on previous medication of kidney disease, in most cases does not create complications leading to earlier drug cessation. In the case of glomerulonephritis also does not bear an increased risk of relapse of main disease.
本研究旨在评估1994年至2002年期间曾因肾病指征接受治疗的儿童慢性肝炎的治疗效果。
在开始应用干扰素(INF)治疗时,对42名年龄为10.2±4.8岁的儿童进行了检查。其中30名儿童(71.4%)为慢性乙肝病毒感染,8名(19.1%)为丙肝病毒感染,4名(9.5%)为乙肝和丙肝病毒混合感染且处于复制期。在接受检查的儿童中,先前有26名(61.9%)报告有肾小球肾炎症状,17名(40.5%)有肾病综合征症状;9名(21.4%)观察到慢性肾衰竭。22名儿童接受了泼尼松治疗。评估了治疗前、治疗期间以及治疗终止后6个月和12个月时白蛋白、γ-球蛋白、胆红素、血红蛋白、肌酐、血细胞比容、白细胞增多、丙氨酸转氨酶(ALT)活性、慢性肝炎标志物的浓度。应用了干扰素α-2a、α-2b和重组人干扰素α。
22名(52.4%)儿童治疗前ALT值不超过100 IU/l。对39名儿童进行了肝活检。其中18名(46.2%)显示炎症过程活动度高;其中只有5名ALT活性高于100 IU/l。治疗开始时白细胞增多越明显,炎症过程的活动度越低。34名儿童中有14名HBe标志物发生血清学转换,12名丙肝病毒感染儿童中有4名在第1疗程干扰素治疗后丙肝病毒RNA清除。只有5名(11.9%)儿童因副作用(与尿路无关)停止治疗,1名因原发病复发停止治疗。13名儿童进行了第2疗程治疗。其中2名获得了HBe标志物血清学转换。
鉴于受检儿童数量较少,无法对慢性肝炎的治疗效果进行全面评估。其效果似乎与无肾病风险的儿童群体中观察到的情况相当。对曾接受肾病治疗的儿童进行干扰素治疗,在大多数情况下不会产生导致提前停药的并发症。对于肾小球肾炎,也不会增加原发病复发的风险。